Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action

Fig. 2

Treatment of Panc-1 cells with dasatinib decreases the sensitivity of TGF-β/Smad-responsive reporters to TGF-β1 stimulation. Panc-1 cells were transfected on day 1 with either pCAGA(12)-luc (upper graph) or 3TPlux (lower graph), and the Renilla luciferase-encoding vector pRL-TK-luc using LipofectAmine 2000. Twenty-four h after the start of transfection, cells were stimulated with TGF-β1 for another 24-h period in the presence of 0.1 % DMSO or the indicated concentrations of dasatinib, SB431542, or bosutinib, followed by dual luciferase measurements. Data represent firefly luciferase values normalised with those for Renilla luciferase (displayed as relative (rel.) luciferase activities with those for DMSO/non-TGF-β1-treated cells set arbitrarily at 1) and are the mean ± SD from three independent assays. Asterisks indicate significance of TGF-β1-treated cells vs. the respective untreated control (n = 3)

Back to article page

Molecular Cancer

ISSN: 1476-4598